VAXXINITY INC-A (VAXX) Stock Price, Quote, News and Overview
NASDAQ:VAXX - Nasdaq - US92244V1044 - Common Stock - Currency: USD
VAXX Quote, Performance and Key Statistics
0.1111
-0.02 (-15.26%)
The current stock price of VAXX is 0.1111 USD. In the past month the price decreased by -81.79%. In the past year, price decreased by -94.42%.
VAXX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.06 | 358.78B | ||
| AMGN | AMGEN INC | 15.32 | 163.05B | ||
| GILD | GILEAD SCIENCES INC | 23.96 | 137.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1668.52 | 124.31B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.53B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.21B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.31B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.46B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.22B | ||
| NTRA | NATERA INC | N/A | 21.36B | ||
| BIIB | BIOGEN INC | 8.52 | 20.45B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.50B |
Related stock screener links
About VAXX
Company Profile
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas and currently employs 87 full-time employees. The company went IPO on 2021-11-11. The firm is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) has enabled the innovation of pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimers, Parkinsons, migraine, and hypercholesterolemia. Its pipeline consists of six programs, which include UB-311, UB-312, VXX-301, UB-313, VXX-401 and UB-612. Its UB-311 targets toxic forms of aggregated amyloid-b (Ab) in the brain to fight AD. Its UB-312 targets toxic forms of aggregated a-synuclein in the brain to fight PD and other synucleinopathies, such as Lewy body dementia (LBD) and multiple system atrophy (MSA). Its UB-313 targets Calcitonin Gene-Related Peptide (CGRP) to fight migraines.
Company Info
VAXXINITY INC-A
1717 Main Street, Suite 3388
Dallas TEXAS US
Employees: 87
Company Website: https://vaxxinity.com/
Phone: 12542445739
VAXXINITY INC-A / VAXX FAQ
What is the stock price of VAXXINITY INC-A today?
The current stock price of VAXX is 0.1111 USD. The price decreased by -15.26% in the last trading session.
What is the ticker symbol for VAXXINITY INC-A stock?
The exchange symbol of VAXXINITY INC-A is VAXX and it is listed on the Nasdaq exchange.
On which exchange is VAXX stock listed?
VAXX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VAXXINITY INC-A stock?
8 analysts have analysed VAXX and the average price target is 15.3 USD. This implies a price increase of 13671.38% is expected in the next year compared to the current price of 0.1111. Check the VAXXINITY INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VAXXINITY INC-A worth?
VAXXINITY INC-A (VAXX) has a market capitalization of 14.08M USD. This makes VAXX a Nano Cap stock.
How many employees does VAXXINITY INC-A have?
VAXXINITY INC-A (VAXX) currently has 87 employees.
What are the support and resistance levels for VAXXINITY INC-A (VAXX) stock?
VAXXINITY INC-A (VAXX) has a resistance level at 0.12. Check the full technical report for a detailed analysis of VAXX support and resistance levels.
Should I buy VAXXINITY INC-A (VAXX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VAXX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VAXX, evaluating the profitability, health, valuation and growth aspects
- VAXXINITY INC-A (VAXX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VAXXINITY INC-A (VAXX) Sales and EPS estimates to see what analysts future expectations are.
- VAXXINITY INC-A (VAXX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VAXXINITY INC-A (VAXX) Insider and Institutional Ownership to learn about the owners and their transactions.
- VAXXINITY INC-A (VAXX) Stock Chart to make your own analysis
- VAXXINITY INC-A (VAXX) Latest news and press-releases to stay up to date.
Does VAXXINITY INC-A (VAXX) stock pay dividends?
VAXX does not pay a dividend.
When does VAXXINITY INC-A (VAXX) report earnings?
VAXXINITY INC-A (VAXX) will report earnings on 2024-08-07, after the market close.
What is the Price/Earnings (PE) ratio of VAXXINITY INC-A (VAXX)?
VAXXINITY INC-A (VAXX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.45).
What is the Short Interest ratio of VAXXINITY INC-A (VAXX) stock?
The outstanding short interest for VAXXINITY INC-A (VAXX) is 0.48% of its float. Check the ownership tab for more information on the VAXX short interest.
VAXX Technical Analysis
VAXX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to VAXX. VAXX has a bad profitability rating. Also its financial health evaluation is rather negative.
VAXX Financial Highlights
Over the last trailing twelve months VAXX reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS increased by 25.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -128.51% | ||
| ROE | -424.66% | ||
| Debt/Equity | 0.99 |
VAXX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to VAXX. The Buy consensus is the average rating of analysts ratings from 8 analysts.